Lv3
268 积分 2023-06-02 加入
Safety and efficacy of mepolizumab in eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-analysis
11小时前
已完结
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
11小时前
已完结
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
11小时前
已完结
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
11小时前
已完结
Role of Cytokines IL-25, IL-33, and TSLP in the Respiratory Tract Inflammation: Therapeutic Perspectives
11小时前
已完结
“Beyond triple Therapy: Is dupilumab a cost-effective option for COPD with type 2 inflammation?"
11小时前
求助中
Efficacy without resolution: A critical appraisal of mepolizumab in eosinophilic COPD
11小时前
已完结
Eosinophilic Versus Non-Eosinophilic Acute Exacerbations of COPD and Subsequent Cardiovascular Event
11小时前
已完结
Blood eosinophil count as a biomarker for therapy guidance in COPD and asthma exacerbations
13小时前
已关闭
Structural characterization of a human Fc fragment engineered for extended serum half-life
14小时前
已完结
皖公网安备34019202002308
